Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Gain Therapeutics Q2 2024 GAAP EPS $(0.42) Misses $(0.20) Estimate

Author: Benzinga Newsdesk | August 08, 2024 07:49am
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.20) by 110 percent. This is a 32.26 percent increase over losses of $(0.62) per share from the same period last year.

Posted In: GANX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist